<DOC>
	<DOCNO>NCT00915408</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) evaluate safety cyclophosphamide give day 1 8 28 day cycle dose start 300mg range 700mg combination Lenalidomide ( Revlimid® ) plus dexamethasone patient present relapsed refractory myeloma .</brief_summary>
	<brief_title>A Dose Escalation Study Combination Lenalidomide ( Revlimid® ) , Dexamethasone Cyclophosphamide Patients Refractory Relapsing From Stable Disease With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age &gt; 18 year time signing informed consent form . 3 . Proven diagnosis multiple myeloma . 4 . Relapse Refractory disease evidence progression least 2 cycle antimyeloma treatment . 5 . Relapse refractory disease evidence progressive disease least 1 previous therapy may include consolidation induction stem cell transplant ) . 6 . Subjects may previously treat thalidomide and/or radiation therapy . In addition , radiation therapy initiate prior baseline ( Day 1 ) must complete prior initiation therapy . The initiation radiation therapy baseline ( Day 1 ) consider treatment failure ( except give treat promote heal pathological fracture ) . 7 . Measurable level myeloma paraprotein serum ( &gt; 5 gms/L ) urine &gt; 2 g excrete 24hour collection sample ) . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 2 . 9 . Able adhere study visit schedule protocol requirement . 10 . Women childbearing potential ( WCBP ) must negative serum urine pregnancy test within 10 14 day within 24 hour start study drug . In addition , sexually active WCBP must agree continued abstinence heterosexual intercourse use adequate contraceptive method start 4 week prior initiation therapy . WCBP must agree pregnancy test weekly first 4 week , monthly study drug ( every 14 day woman irregular cycle ) 4 week last dose study drug . Men must also agree use condom partner child bear potential , even successful vasectomy . 11 . Disease free prior malignancy equal 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` insitu '' cervix breast . 12 . Able receive low dose aspirin ( e.g . 75mg ) prophylactic anticoagulant medication prevent thromboembolism unless contraindicate . If low dose aspirin contraindicate , subject receive another form anticoagulant prophylaxis accord hospital guideline . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 2 . Pregnant lactating female . 3 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1.000 cells/mm3 ( 1.0 x 109/L ) 2 . Platelet count &lt; .75.000/mm3 ( 75 x 109L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 umol/L ) 4 . Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 umol/L ) 4 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 5 . Known hypersensitivity thalidomide , dexamethasone cyclophosphamide . 6 . Prior history uncontrollable side effect dexamethasone therapy 7 . The development desquamate rash take thalidomide 8 . Any prior use Lenalidomide ( Revlimid® ) 9 . Use standard/experimental antimyeloma drug therapy within 28 day entry use experimental nondrug therapy ( e.g . donor leukocyte/mononuclear cell infusion ) within 56 day entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>